Abstract
The simultaneous presentation of chronic lymphocytic leukaemia (CLL) and cutaneous T-cell lymphoma (CTCL) is a very rare occurrence where optimal treatment is unknown. We present the case of a 65-yr-old man who was successfully treated with alemtuzumab monotherapy for both disorders, but at a cost of severe infectious morbidity and prolonged pancytopenia.
MeSH terms
-
Absidia
-
Aged
-
Alemtuzumab
-
Anti-Infective Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / therapeutic use*
-
Aspergillosis / drug therapy
-
Aspergillosis / etiology
-
Cellulitis / etiology
-
Cytomegalovirus Infections / drug therapy
-
Cytomegalovirus Infections / etiology
-
Humans
-
Immunization, Passive* / adverse effects
-
Immunocompromised Host
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Male
-
Mucormycosis / drug therapy
-
Mucormycosis / etiology
-
Neoplasms, Multiple Primary / therapy*
-
Pancytopenia / etiology
-
Remission Induction
-
Sezary Syndrome / therapy*
-
Sinusitis / etiology
Substances
-
Anti-Infective Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Alemtuzumab